| Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study S Kunte, L Rybicki, A Viswabandya, R Tamari, A Bashey, A Keyzner, ... Leukemia 36 (3), 856-864, 2022 | 29 | 2022 |
| Uranyl peroxide pyrophosphate cage clusters with oxalate and nitrate bridges J Ling, M Ozga, M Stoffer, PC Burns Dalton Transactions 41 (24), 7278-7284, 2012 | 28 | 2012 |
| Hybrid uranyl-carboxyphosphonate cage clusters PO Adelani, M Ozga, CM Wallace, J Qiu, JES Szymanowski, GE Sigmon, ... Inorganic Chemistry 52 (13), 7673-7679, 2013 | 25 | 2013 |
| AL amyloidosis: the effect of fluorescent in situ hybridization abnormalities on organ involvement and survival M Ozga, Q Zhao, D Benson Jr, P Elder, N Williams, N Bumma, A Rosko, ... Cancer Medicine 10 (3), 965-973, 2021 | 14 | 2021 |
| Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis N Mehta-Shah, A Kommalapati, S Teja, AF Cashen, PB Dahi, CS Sauter, ... Blood 136, 35-36, 2020 | 14 | 2020 |
| AL amyloidosis: the effect of maintenance therapy on autologous stem cell transplantation outcomes M Ozga, Q Zhao, D Benson, P Elder, N Williams, N Bumma, A Rosko, ... Journal of Clinical Medicine 9 (11), 3778, 2020 | 8 | 2020 |
| The incidence of invasive fungal infections in patients with AML treated with a hypomethylating agent M Ozga, Y Huang, JS Blachly, NR Grieselhuber, S Wall, K Larkin, ... Clinical Lymphoma Myeloma and Leukemia 21 (1), e76-e83, 2021 | 6 | 2021 |
| The effect of cytogenetic abnormalities on organ involvement and survival in patients with AL amyloidosis M Ozga, Q Zhao, DM Benson Jr, P Elder, N Williams, N Bumma, ... Blood 134, 1833, 2019 | 6 | 2019 |
| Haploidentical allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide in patients with myelofibrosis: a multi-institutional experience SJ Kunte, L Rybicki, A Viswabandya, A Bashey, M Iqbal, MR Grunwald, ... Blood 136, 33-34, 2020 | 4 | 2020 |
| Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG) M Ozga, D Nicolet, K Mrózek, AS Yilmaz, J Kohlschmidt, KT Larkin, ... Leukemia 38 (1), 45-57, 2024 | 3 | 2024 |
| Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia JE Maakaron, MP Ozga, GN Mannis, W Pulley, MC Foster, JF Zeidner, ... Annals of hematology 99, 1411-1413, 2020 | 3 | 2020 |
| Concomitant 1q+ and t (4; 14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma M Ozga, Q Zhao, L Huric, C Miller, A Rosko, A Khan, E Umyarova, ... Blood Cancer Journal 13 (1), 167, 2023 | 2 | 2023 |
| Outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed/refractory multiple myeloma: a single-institution experience AM Khan, M Ozga, H Bhatt, MS Faisal, S Ansari, Q Zhao, N Bumma, ... Clinical Lymphoma Myeloma and Leukemia 23 (3), e182-e189, 2023 | 2 | 2023 |
| Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms M Ozga, J Blachly, AK Eisfeld, N Grieselhuber, K Larkin, A Walker, ... American journal of hematology 96 (7), E223-E225, 2021 | 2 | 2021 |
| AL amyloidosis: the effects of maintenance therapy on autologous stem cell transplantation outcomes M Ozga, Q Zhao, DM Benson Jr, P Elder, N Williams, N Bumma, ... Blood 134, 2029, 2019 | 2 | 2019 |
| The co-occurrence of 1q21+/1q23+ and t (4; 14) abnormalities with specific clone size is predictive of shorter response to transplant in patients with multiple myeloma MP Ozga, Q Zhao, N Bumma, AE Rosko, A Khan, S Devarakonda, ... Blood 140 (Supplement 1), 9993-9994, 2022 | 1 | 2022 |
| AL Amyloidosis: the prognostic impact of maintenance therapy following ASCT MP Ozga, Q Zhao, DM Benson, P Elder, N Williams, N Bumma, A Rosko, ... Biology of Blood and Marrow Transplantation 26 (3), S229-S230, 2020 | 1 | 2020 |
| I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non-Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of … MP Ozga, KM Dvorak-Kornaus, Q Zhao, J Buss, A Laganson, E Hamp, ... Blood 142, 1534, 2023 | | 2023 |
| Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2 K Annunzio, M Ozga, Y Huang, M Anghelina, SA Bhat, JS Blachly, ... EJHaem 4 (4), 1200, 2023 | | 2023 |
| Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML)(AMLCG, CALGB [Alliance]) MP Ozga, D Nicolet, K Mrózek, S Yilmaz, J Kohlschmidt, KT Larkin, ... Blood 140 (Supplement 1), 936-939, 2022 | | 2022 |
